BERKELEY, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the promotion of Dirk Brockstedt, Ph.D., to executive vice president, research and development; Nancy Kaplan to vice president, human resources and facility operations; Anne Moon, Ph.D., to vice president, project management and team leader; and Justin Skoble, Ph.D., to vice president, technical operations.
“The leadership and expertise contributed by each of these individuals has been instrumental in building Aduro into a leader in the immunotherapy field with three diverse technology platforms, a deep product pipeline and relationships with leading pharmaceutical companies including Novartis and Janssen,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “As we move toward commercialization, these promotions reflect our ongoing efforts to ensure that we have the right personnel leading the teams responsible for these critical functions.”
Dirk Brockstedt, Ph.D., has been promoted to the position of executive vice president of research and development. He joined Aduro in 2009 and most recently served as Aduro’s senior vice president of research and development. Prior to joining Aduro, Dr. Brockstedt held escalating positions in the immunology department of Cerus Corporation, most recently as director of immunology. Prior to Cerus Corporation, he was a scientist at Aventis in the immunotherapy and anti-angiogenesis group, developing novel therapies against cancer. Dr. Brockstedt holds an M.S. in Microbiology from the University of Kiel (Germany), earned his Ph.D. from the University of Kiel and Stanford University and was a post-doctoral fellow at the Stanford School of Medicine in the department of Pathology.
Nancy Kaplan has been promoted to vice president of human resources and facility operations. She joined Aduro in 2008 and most recently served as Aduro’s senior director of human resources and facility operations. Prior to Aduro, Ms. Kaplan worked with a wide variety of small biotech companies applying her broad generalist skill set to establish and bolster finance, human resources, facility management, grant administration and investor relations functions. In addition, she was marketing communications manager at Applied Biosystems and supervised biotech accounts at Lena Chow Advertising. Previously, Ms. Kaplan was part of the founding group at Invitron Corp, a mammalian cell contract manufacturer. Ms. Kaplan holds a B.S. in Agronomy from Oregon State University.
Anne Moon, Ph.D., has been promoted to vice president of project management and team leader. She joined Aduro in 2014 and most recently served as Aduro’s executive director of program and alliance management. Prior to Aduro, Dr. Moon was a founding team member of Jennerex Biotherapeutics (acquired by SillaJen), where she served as vice president of product development. Prior to Jennerex, Dr. Moon was part of the start-up team at Cytokinetics, establishing the cell-based screening program. Before that, she served as project manager of the oncolytic virus program at Onyx Pharmaceuticals (acquired by Amgen) after completing postdoctoral work within the small molecule therapeutics program targeting small GTPases. She received her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley and her B.A. in Biology from Harvard University.
Justin Skoble, Ph.D., has been promoted to vice president of technical operations. He joined Aduro in 2009 and most recently served as Aduro’s senior director of technical operations. Prior to Aduro, Dr. Skoble held escalating positions in the molecular biology and process development departments at Anza Therapeutics and Cerus Corporation. He earned his B.A. in Biology from Vassar College and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley in the laboratory of Dr. Daniel Portnoy. Additionally, Dr. Skoble performed postdoctoral work at the University of California, San Francisco in the laboratory of Dr. Jeff Cox.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology, plans, timing and the availability of results of our clinical trials and the potential for eventual regulatory approval and commercialization of our product candidates. In some cases you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended March 31, 2016 which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 firstname.lastname@example.org Mike Beyer Sam Brown, Inc. 312-961-2502
Source:Aduro Biotech, Inc.